Media formats available:
Dual Inhibitor Gets the Nod. The selective serotonin and norepinephrine dual reuptake inhibitor milnacipran (Savella, Forest Laboratories and Cypress Bioscience) received FDA approval for management of fibromyalgia. Two phase III trials of milnacipran 100mg/day and 200mg/day demonstrated statistically significantly and clinically meaningful concurrent improvements in pain, patient global assessment and physical function. In both studies, at three months a greater proportion of patients in the treatment arms experienced at least a 30 percent reduction in pain from baseline and rated themselves as "very much improved" or "much improved" on the PGA compared to controls, the companies report. Savella will hit pharmacy shelves next month.
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- Practice Management
Practice Management: Billing & Coding — What’s the 411 on G2211?
Brad C. Klein, MD, MBA; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSBrad C. Klein, MD, MBA; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS - Practice Management
The Whole Physician: Ten Action Items to Combat Peer-to-Peer and Institutional Racial Bias in Medicine
Jerome Lisk, MD, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHSJerome Lisk, MD, FAAN; Paul G. Mathew, MD, DNBPAS, FAAN, FAHS - Headache & Pain
Practice Management: Botulinum Toxin Billing & Coding Update
Martin T. Taylor, DO, PhD; Laxman Bahroo, DO, FAANMartin T. Taylor, DO, PhD; Laxman Bahroo, DO, FAAN
